Hypertrophic cardiomyopathy secondary prevention: Difference between revisions
No edit summary |
(→ICD) |
||
Line 17: | Line 17: | ||
===ICD=== | ===ICD=== | ||
Indications for | Indications for implantable cardioverter-defibrillator (Secondary prevention) | ||
* Survivors of cardiac arrest | * Survivors of cardiac arrest | ||
* Sustained spontaneous ventricular | * Sustained spontaneous ventricular arrhythmia | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 00:43, 28 January 2020
Hypertrophic Cardiomyopathy Microchapters |
Differentiating Hypertrophic Cardiomyopathy from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hypertrophic cardiomyopathy secondary prevention On the Web |
Hypertrophic cardiomyopathy secondary prevention in the news |
Directions to Hospitals Treating Hypertrophic cardiomyopathy |
Risk calculators and risk factors for Hypertrophic cardiomyopathy secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Effective measures for the secondary prevention of hypertrophic cardiomyopathy include screening. Once HCM has been identified in a family, immediate testing of all family members will help to identify those at risk. Both imaging and genetic testing might be helpful. Athletes and military commanders (this in danger group barely discussed in the literature) are particularly in danger and it is recommended to undergo screening for HCM.
Secondary Prevention
Effective measures for the secondary prevention of hypertrophic cardiomyopathy include screening by means of:
- Echocardiography
- MRI
- Genetic testing
Athletes and military commanders (this in danger group barely discussed in the literature) are particularly in danger and it is recommended to undergo screening for HCM.
ICD
Indications for implantable cardioverter-defibrillator (Secondary prevention)
- Survivors of cardiac arrest
- Sustained spontaneous ventricular arrhythmia